Peptides derived from a secretory yeast library restore factor VIII activity in the presence of an inhibitory antibody

Biotechnology and Bioengineering

Volumn 98, Issue 1, 2007, Pages 12-21

  Mersich, Christa ^a   Billes, Werner ^a   Pabinger, Ingrid ^b   Jungbauer, Alois ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood coagulation; Eif5a; Protein; Protein secretion; Random peptide library; Yeast

Indexed keywords

BLOOD COAGULATION; EIF5A; PROTEIN SECRETION; RANDOM PEPTIDE LIBRARY;

ANTIBODIES; ENZYME ACTIVITY; MOLECULAR INTERACTIONS; YEAST;

AMINO ACIDS;

BLOOD CLOTTING FACTOR 8 ANTIBODY; INITIATION FACTOR 5A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ESH8; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; COMPUTER PROGRAM; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; PREDICTION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN STRUCTURE;

ANTIBODIES; FACTOR VIII; HEMOPHILIA A; HUMANS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN ENGINEERING; YEASTS;

EUKARYOTA; MURINAE;

EID: 34548254096     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21426     Document Type: Article

References (36)

1. Ahmad SS, Walsh PN. 2005. Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane. Biochemistry 44(42):13858-13865.
2. Baudo F, Redaelli R, Caimi TM, Mostarda G, Somaini G, de Cataldo F. 2000. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 99(1):21-24.
3. Berendsen HJC, van der Spoel D, van Drunen R. 1995. GROMACS: A message-passing parallel molecular dynamics implementation. Comput Phys Commun 91(1-3):43-56.
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The protein data bank. Nucleic Acids Res 28(1):235-242.
5. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15(6):553-557.
6. Cornelius RM, Dahri L, Boisson-Vidal C, Muller D, Jozefonvicz J, Brash JL. 1997. Adsorption of immunoglobulin G and anti-factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes. Biomaterials 18(5):429-436.
7. Ehrenforth S, Kreuz W, Scharrer I, Kornhuber B. 1992a. Factor VIII inhibitors in haemophiliacs. Lancet 340(8813):253.
8. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. 1992b. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339(8793):594-598.
9. Ehrlich HJ, Henzl MJ, Gomperts ED. 2002. Safety of factor VIII inhibitor bypass activity (FEIBA(R)): 10-year compilation of thrombotic adverse events. Haemophilia 8(2):83-90.
10. Facchiano AM, Stiuso P, Chiusano ML, Caraglia M, Giuberti G, Marra M, Abbruzzese A, Colonna G. 2001. Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A). Protein Eng 14(11):881-890.
11. Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. 1988. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 82(1):123-128.
12. Gietz RD, Woods RA. 2002. Transformation of yeast by lithium acetate/ single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol 350:87-96.
13. Green D, Lechner K. 1981. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 45(3):200-203.
14. Guex N, Peitsch MC. 1997. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18(15):2714-2723.
15. Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P. 1995. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270(24):14505-14509.
16. Healey JF, Barrow RT, Tamim HM, Lubin IM, Shima M, Scandella D, Lollar P. 1998. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 92(10):3701-3709.
17. Holz C, Lueking A, Bovekamp L, Gutjahr C, Bolotina N, Lehrach H, Cahill DJ. 2001. A human cDNA expression library in yeast enriched for open reading frames. Genome Res 11(10):1730-1735.
18. Kieke MC, Cho BK, Boder ET, Kranz DM, Wittrup KD. 1997. Isolation of anti-T cell receptor scFv mutants by yeast surface display. Protein Eng 10(11):1303-1310.
19. Kopecky EM, Greinstetter S, Pabinger I, Buchacher A, Romisch J, Jungbauer A. 2005. Combinatorial peptides directed to inhibitory antibodies against human blood clotting factor VIII. Thromb Haemost 94(5): 933-941.
20. Nogami K, Shima M, Nakai H, Tanaka I, Suzuki H, Morichika S, Shibata M, Saenko EL, Scandella D, Giddings JC. et al. 1999. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: Requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol 107(1):196-203.
21. Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM. et al. 1999. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 93(7):2267-2273.
22. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D. 1997. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate Kogenate Study Groups Blood 89(10):3663-3671.
23. Prickett KS, Amberg DC, Hopp TP. 1989. A calcium-dependent antibody for identification and purification of recombinant proteins. Biotechniques 7(6):580-589.
24. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM. 2000. Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 84(4):643-652.
25. Rost B, Yachdav G, Liu J. 2004. The PredictProtein server. Nucleic Acids Res 32: (Web Server issue): W321-W326.
26. Saenko EL, Shima M, Gilbert GE, Scandella D. 1996. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 271(44):27424-27431.
27. Salooja N, Kemball-Cook G, Tuddenham EG, Dyson J. 2002. Use of a nondepleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. Br J Haematol 118(3):839-842.
28. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
29. Scandella D, Mattingly M, Prescott R. 1993. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 82(6):1767-1775.
30. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. 1995. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86(5):1811-1819.
31. Schuster M, Einhauer A, Wasserbauer E, Sussenbacher F, Ortner C, Paumann M, Werner G, Jungbauer A. 2000a. Protein expression in yeast; comparison of two expression strategies regarding protein maturation. J Biotechnol 84(3):237-248.
32. Schuster M, Wasserbauer E, Einhauer A, Ortner C, Jungbauer A, Hammerschmid F, Werner G. 2000b. Protein expression strategies for identification of novel target proteins. J Biomol Screen 5(2):89-97.
33. Scott JK, Smith GP. 1990. Searching for peptide ligands with an epitope library. Science 249(4967):386-390.
34. Smith GP. 1985. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228(4705):1315-1317.
35. Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C. 2002. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody E SH8. J Biol Chem 277(30):27232-27239.
36. Villard S, Lacroix-Desmazes S, Kieber-Emmons T, Piquer D, Grailly S, Benhida A, Kaveri SV, Saint-Remy JM, Granier C. 2003. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 102(3):949-952.